Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28048524 | 0.91 | MAPK1 (0.64) | MAPK1CYP19A1CYP11B1CYP11B2MAOA | |
| SCHEMBL7311175 | 0.84 | MAPK1 (0.65) | MAPK1GPR132MEN1KMT2AHTR1A | |
| SCHEMBL171895 | 0.83 | MAPK1 (0.56) | MAPK1CYP19A1CYP11B1CYP11B2MAOA | |
| SCHEMBL8881389 | 0.83 | HTT (0.62) | MAPK1CYP19A1CYP11B1CYP11B2APP | |
| SCHEMBL30896277 | 0.83 | RAB9A (0.61) | MAPK1APPMAOARAB9AHTT | |
| SCHEMBL24932986 | 0.83 | RAB9A (0.61) | MAPK1APPMAOARAB9AHTT | |
| SCHEMBL3761776 | 0.83 | MAOB (0.62) | MAPK1CYP19A1CYP11B1CYP11B2APP | |
| SCHEMBL8361615 | 0.83 | MAPK1 (0.56) | MAPK1CYP19A1CYP11B1CYP11B2APP | |
| SCHEMBL8041706 | 0.83 | MAPK1 (0.56) | MAPK1CYP19A1CYP11B1CYP11B2MAOA | |
| SCHEMBL30354931 | 0.83 | MAOB (0.62) | MAPK1CYP19A1CYP11B1CYP11B2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| EP-1560834-B1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | disclosed |
| EP-1560834-B1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | disclosed |
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-01 | — | — | US | disclosed |
| EP-1560834-A1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004043966-A1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003033467-A1 | NITROSO DIPHENYLAMINE DERIVATIVES AS NITROGEN MONOXIDE GENERATING AGENTS | MERCK PATENT GMBH (DE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LTA4H, LTC4S, LTB4R2 | MAPK1 1947/4885CYP19A1 1505/4885CYP11B1 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.